<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597164</url>
  </required_header>
  <id_info>
    <org_study_id>PL13</org_study_id>
    <nct_id>NCT04597164</nct_id>
  </id_info>
  <brief_title>Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF</brief_title>
  <official_title>Combination of Double Plasma Molecular Adsorption System and Low Volume Plasma Exchange for Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure, a Multicenter Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the clinical efficacy and safety of non-bioartificial liver&#xD;
      support system combination treatment with double plasma molecular adsorption system and low&#xD;
      volume plasma exchange in patients with hepatitis b virus related acute-on-chronic liver&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis b virus (HBV) related acute-on-chronic liver failure (ACLF) is a serious condition&#xD;
      with high mortality rate in China. But there still lacks of effective therapies in treatment&#xD;
      of HBV related ACLF, except liver transplantation. Non-bioartificial liver support system&#xD;
      treatments may be effective due to previous clinical data. Plasma exchange (PE) and double&#xD;
      plasma molecular adsorption system (DPMAS) are two common ways in clinical practice. This&#xD;
      study is to investigate the clinical efficacy and safety of combination treatment of DPMAS&#xD;
      and low volume PE in patients with HBV related ACLF. This study will be completed in 6&#xD;
      medical center. Two hundred patients with HBV related ACLF enrolled in this study are&#xD;
      randomized grouping into trial group (DPMAS, low volume PE, and comprehensive internal&#xD;
      medical treatment) and control group (comprehensive internal medical treatment). Symptoms,&#xD;
      signs, laboratory tests results, adverse events, mortality rates are recorded from treatment&#xD;
      baseline to 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>48 weeks</time_frame>
    <description>Cumulative rate of death at 48 weeks after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Model for end-stage liver disease (MELD) score variation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Variation of MELD score at 48 weeks after treatment. MELD score = 9.57 × loge(creatinine mg/dl) + 3.78 × loge(TBIL mg/dl) + 11.20 × loge(PT-INR) + 6.43.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Artificial liver support system group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patients in this group will receive treatment of double plasma molecular adsorption system, low volume plasma exchange, and comprehensive internal medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comprehensive medical treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>100 patients in this group will receive comprehensive internal medical treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Artificial liver support system</intervention_name>
    <description>Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.</description>
    <arm_group_label>Artificial liver support system group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b&#xD;
             surface antigen or positive hepatitis b virus DNA &gt; 0.5 year);&#xD;
&#xD;
          2. Age from 18 to 65 years old;&#xD;
&#xD;
          3. Clinical diagnosis of liver failure (serum total bilirubin level &gt; 10 times upper&#xD;
             limit of normal; prothrombin time activity &lt; 40% and ≥20%, or prothrombin time&#xD;
             international ratio ≤ 2.6 and &gt; 1.5);&#xD;
&#xD;
          4. Platelets &gt; 50*10 E9/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other active liver diseases;&#xD;
&#xD;
          2. Hepatocellular carcinoma or other malignancy;&#xD;
&#xD;
          3. Pregnancy or lactation;&#xD;
&#xD;
          4. Human immunodeficiency virus infection or congenital immune deficiency diseases;&#xD;
&#xD;
          5. Severe diabetes, autoimmune diseases; unstable infarction due to&#xD;
             cardio-cerebrovascular events;&#xD;
&#xD;
          6. Other important organ dysfunctions or transplantation;&#xD;
&#xD;
          7. Severe complications including severe infection, gastrointestinal bleeding, hepatic&#xD;
             encephalopathy, hepatorenal syndrome;&#xD;
&#xD;
          8. Patients can not follow-up;&#xD;
&#xD;
          9. Investigator considering inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiong Xu, Doctor</last_name>
    <phone>+8613760783281</phone>
    <email>xwx1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatitis b virus</keyword>
  <keyword>acute-on-chronic liver failure</keyword>
  <keyword>double plasma molecular adsorption system</keyword>
  <keyword>plasma exchange</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol, results and conclusions of this clinical trial will be published at academic conferences or in journals.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to pliang@mail.sysu.edu.cn. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

